Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets solutions for management of dermatological conditions and advanced tissue care. The Company's product portfolio consists of dermatology, animal health, and advanced tissue care products based upon its Microcyn technology. Its Microcyn technology family of products consists of liquids and gels, which contain small molecule oxychlorine compounds. Its products serve patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.
No insider trading activity.
Insider trading information report provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.